SELECTA BIOSCIENCES INC (40) | License Agreements (4)

Recent Contracts

Fifth Amendment to Exclusive Patent License Agreement, dated as of May 15, 2020, by and between the Registrant and the Massachusetts Institute of Technology (Filed With SEC on August 6, 2020)
License and Development Agreement, dated as of June 11, 2020, by and between the Registrant and Swedish Orphan Biovitrum AB (Publ) (Filed With SEC on August 6, 2020)
Fourth Amendment to Exclusive Patent License Agreement, entered into on December 13, 2019, by and between the Massachusetts Institute of Technology and the Registrant (Filed With SEC on March 12, 2020)
Feasibility Study and License Agreement by and between Asklepios BioPharmaceutical, Inc. and Selecta Biosciences, Inc. dated August 6, 2019 (Filed With SEC on November 8, 2019)